


Claims:

## 1. Compound of the formula



where

R<sub>1</sub> is a) hydrogen, hydroxyl or amino; or

b) C<sub>1</sub>-C<sub>8</sub>-alkyl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl, C<sub>1</sub>-C<sub>8</sub>-alkanoyl, C<sub>1</sub>-C<sub>8</sub>-alkoxycarbonyl, aryl-C<sub>0</sub>-C<sub>4</sub>-alkyl or heterocyclyl-C<sub>0</sub>-C<sub>4</sub>-alkyl, which radicals may be substituted by 1-4 C<sub>1</sub>-C<sub>8</sub>-alkyl, halogen, oxo, cyano, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub>-alkoxy, C<sub>1</sub>-C<sub>8</sub>-alkoxycarbonyl, aryl or heterocyclyl;

R<sub>2</sub> is a) C<sub>1</sub>-C<sub>8</sub>-alkyl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl, C<sub>1</sub>-C<sub>8</sub>-alkylsulphonyl, C<sub>3</sub>-C<sub>8</sub>-cycloalkylsulphonyl, aryl-C<sub>0</sub>-C<sub>8</sub>-alkylsulphonyl, heterocyclylsulphonyl, C<sub>3</sub>-C<sub>12</sub>-cycloalkyl-C<sub>1</sub>-C<sub>8</sub>-alkanoyl, aryl-C<sub>1</sub>-C<sub>8</sub>-alkanoyl, aryl-C<sub>3</sub>-C<sub>8</sub>-cycloalkanoyl, C<sub>1</sub>-C<sub>8</sub>-alkanoyl, C<sub>1</sub>-C<sub>8</sub>-alkoxycarbonyl, optionally N-mono- or N,N-di-C<sub>1</sub>-C<sub>8</sub>-alkylated carbamoyl-C<sub>0</sub>-C<sub>8</sub>-alkyl, aryl-C<sub>0</sub>-C<sub>4</sub>-alkyl or heterocyclyl-C<sub>0</sub>-C<sub>4</sub>-alkyl, which radicals may be substituted by 1-4 C<sub>1</sub>-C<sub>8</sub>-alkyl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl, C<sub>3</sub>-C<sub>8</sub>-cycloalkoxy, amino, C<sub>1-6</sub>-alkylamino, di-C<sub>1-6</sub>-alkylamino, C<sub>1</sub>-C<sub>6</sub>-alkanoylamino, C<sub>1</sub>-C<sub>8</sub>-alkoxy-carbonylamino, halogen, oxo, cyano, hydroxyl, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub>-alkoxy, C<sub>1</sub>-C<sub>8</sub>-alkoxycarbonyl, aryl or heterocyclyl; or

b) together with R<sub>1</sub> and the nitrogen atom to which they are bonded is a saturated or partly unsaturated, 4-8-membered, heterocyclic ring which may contain an additional nitrogen, oxygen or sulphur atom or an -SO- or -SO<sub>2</sub>- group, and the additional nitrogen atom may optionally be substituted by C<sub>1</sub>-C<sub>8</sub>-alkyl, C<sub>1</sub>-C<sub>8</sub>-alkanoyl, C<sub>1</sub>-C<sub>8</sub>-alkoxycarbonyl, aryl or heteroaryl radicals, in which case this heterocyclic ring may be part of a bicyclic or tricyclic ring system having a total of up to 16 members and the second ring may also contain a nitrogen, oxygen or sulphur atom or an -SO- or -SO<sub>2</sub>- group, and the nitrogen atom of the second ring may optionally be substituted by C<sub>1</sub>-C<sub>8</sub>-alkyl, C<sub>1</sub>-C<sub>8</sub>-alkanoyl, C<sub>1</sub>-C<sub>8</sub>-alkoxy-carbonyl, aryl or heterocyclyl radicals, and all ring systems mentioned may be substituted by 1-4 C<sub>1</sub>-C<sub>8</sub>-alkyl, halogen, hydroxyl, oxo, trifluoromethyl, C<sub>1</sub>-C<sub>8</sub>-alkoxy, C<sub>1</sub>-C<sub>8</sub>-alkoxy-C<sub>1</sub>-C<sub>8</sub>-alkyl, C<sub>1</sub>-C<sub>8</sub>-alkoxy-C<sub>1</sub>-C<sub>8</sub>-alkoxy, C<sub>1</sub>-C<sub>8</sub>-alkoxycarbonylamino, C<sub>1</sub>-C<sub>8</sub>-alkanoylamino, C<sub>1</sub>-C<sub>8</sub>-alkylamino, N,N-di-C<sub>1</sub>-C<sub>8</sub>-alkylamino, aryl-C<sub>0</sub>-C<sub>4</sub>-alkyl, aryloxy-C<sub>0</sub>-C<sub>4</sub>-alkyl, aryl-C<sub>0</sub>-C<sub>4</sub>-alkyl-

C<sub>1</sub>-C<sub>8</sub>-alkoxy, aryloxy-C<sub>0</sub>-C<sub>4</sub>-alkyl-C<sub>1</sub>-C<sub>8</sub>-alkoxy, heterocyclyl-C<sub>0</sub>-C<sub>4</sub>-alkyl, heterocyclyloxy-C<sub>0</sub>-C<sub>4</sub>-alkyl, heteroaryl-C<sub>0</sub>-C<sub>4</sub>-alkyl-C<sub>1</sub>-C<sub>8</sub>-alkoxy or heterocyclyloxy-C<sub>0</sub>-C<sub>4</sub>-alkyl-C<sub>1</sub>-C<sub>8</sub>-alkoxy;  
 R<sub>3</sub> is hydrogen, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>8</sub>-alkoxycarbonyl or C<sub>1</sub>-C<sub>8</sub>-alkanoyl;  
 R<sub>4</sub> is hydrogen, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>8</sub>-alkoxycarbonyl or C<sub>1</sub>-C<sub>8</sub>-alkanoyl;  
 R<sub>5</sub> is in each case independently hydrogen, C<sub>1</sub>-C<sub>8</sub>-alkyl, or, together with the carbon atom to which they are bonded, are a C<sub>3</sub>-C<sub>8</sub>-cycloalkylidene radical;  
 R<sub>6</sub> is hydrogen or hydroxyl;  
 R, in each case independently, are 1-4 radicals selected from:  
 hydrogen, halogen, C<sub>1</sub>-C<sub>8</sub>-alkyl, 3- to 8-membered cycloalkyl, polyhalo-C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy-C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy-C<sub>1</sub>-C<sub>4</sub>-alkoxy-C<sub>1</sub>-C<sub>4</sub>-alkyl, 3- to 8-membered cycloalkoxy-C<sub>1</sub>-C<sub>4</sub>-alkyl, hydroxyl, C<sub>1</sub>-C<sub>8</sub>-alkanoyloxy-C<sub>1</sub>-C<sub>4</sub>-alkyl, hydroxy-C<sub>2</sub>-C<sub>8</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-alkylthio-C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>8</sub>-alkylsulphonyl-C<sub>1</sub>-C<sub>4</sub>-alkyl, thiazolylthio-C<sub>1</sub>-C<sub>4</sub>-alkyl, thiazolinythio-C<sub>1</sub>-C<sub>4</sub>-alkyl, imidazolylthio-C<sub>1</sub>-C<sub>4</sub>-alkyl, optionally N-oxidized pyridylthio-C<sub>1</sub>-C<sub>4</sub>-alkyl, pyrimidinylthio-C<sub>1</sub>-C<sub>4</sub>-alkyl, optionally partially hydrogenated pyridyl- or N-oxidopyridyl-C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-alkylsulphonylamino-C<sub>1</sub>-C<sub>4</sub>-alkyl, trifluoro-C<sub>1</sub>-C<sub>8</sub>-alkylsulphonylamino-C<sub>1</sub>-C<sub>4</sub>-alkyl, pyrrolidino-C<sub>1</sub>-C<sub>4</sub>-alkyl, piperidino-C<sub>1</sub>-C<sub>4</sub>-alkyl, piperazino-C<sub>1</sub>-C<sub>4</sub>-alkyl, N'-C<sub>1</sub>-C<sub>4</sub>-alkylpiperazino-C<sub>1</sub>-C<sub>4</sub>-alkyl, N'-C<sub>2</sub>-C<sub>8</sub>-alkanoylpiperazino-C<sub>1</sub>-C<sub>4</sub>-alkyl, morpholino-C<sub>1</sub>-C<sub>4</sub>-alkyl, thiomorpholino-C<sub>1</sub>-C<sub>4</sub>-alkyl, S-oxothiomorpholino-C<sub>1</sub>-C<sub>4</sub>-alkyl, S,S-dioxothiomorpholino-C<sub>1</sub>-C<sub>4</sub>-alkyl, cyano-C<sub>1</sub>-C<sub>4</sub>-alkyl, carboxy-C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy-carbonyl-C<sub>1</sub>-C<sub>4</sub>-alkyl, carbamoyl-C<sub>1</sub>-C<sub>8</sub>-alkyl, N-mono- or N,N-di-C<sub>1</sub>-C<sub>4</sub>-alkylcarbamoyl-C<sub>1</sub>-C<sub>4</sub>-alkyl, unsubstituted or mono-, di- or tri-C<sub>1</sub>-C<sub>4</sub>-alkyl-, -C<sub>1</sub>-C<sub>4</sub>-alkoxy-, -hydroxy-, -C<sub>1</sub>-C<sub>4</sub>-alkyl-amino-, -di-C<sub>1</sub>-C<sub>4</sub>-alkylamino-, -halogen- or -trifluoromethyl-substituted phenyl or naphthyl, hydroxy-C<sub>2</sub>-C<sub>8</sub>-alkoxy, halo-C<sub>2</sub>-C<sub>8</sub>-(hydroxy)alkoxy, C<sub>1</sub>-C<sub>8</sub>-alkylsulphonyl-C<sub>1</sub>-C<sub>4</sub>-(hydroxy)-alkoxy, amino-C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-alkylamino-C<sub>1</sub>-C<sub>4</sub>-alkyl, N, N-di-C<sub>1</sub>-C<sub>4</sub>-alkylamino-C<sub>1</sub>-C<sub>4</sub>-alkyl, N-C<sub>1</sub>-C<sub>4</sub>-alkanoylamino-C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>8</sub>-alkoxycarbonylamino-C<sub>1</sub>-C<sub>4</sub>-alkyl, optionally partially hydrogenated pyridyl- or N-oxidopyridyl-C<sub>1</sub>-C<sub>4</sub>-alkyl, piperazino-C<sub>1</sub>-C<sub>4</sub>-alkyl, N'-C<sub>1</sub>-C<sub>4</sub>-alkylpiperazino-C<sub>1</sub>-C<sub>4</sub>-alkyl, N'-C<sub>2</sub>-C<sub>8</sub>-alkanoylpiperazino-C<sub>1</sub>-C<sub>4</sub>-alkyl, morpholino-C<sub>1</sub>-C<sub>4</sub>-alkyl, thiomorpholino-C<sub>1</sub>-C<sub>4</sub>-alkyl, S-oxothiomorpholino-C<sub>1</sub>-C<sub>4</sub>-alkyl, S,S-dioxothiomorpholino-C<sub>1</sub>-C<sub>4</sub>-alkyl, amino-C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-alkylamino-C<sub>1</sub>-C<sub>4</sub>-alkoxy, N,N-di-C<sub>1</sub>-C<sub>4</sub>-alkylamino-C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-alkanoylamino-C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>8</sub>-alkoxycarbonylamino-C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>8</sub>-alkanoyl-C<sub>2</sub>-C<sub>4</sub>-alkoxy which bears the alkanoyl group in a position higher than the  $\alpha$ -position, C<sub>1</sub>-C<sub>8</sub>-alkoxy, 3- to 8-membered cycloalkoxy, C<sub>2</sub>-C<sub>8</sub>-alkenyloxy, 3- to 8-membered cycloalkoxy-C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>8</sub>-alkoxy-C<sub>1</sub>-C<sub>8</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-alkoxy-C<sub>2</sub>-C<sub>4</sub>-alkenyl, C<sub>2</sub>-C<sub>8</sub>-alkenyloxy-C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-alkoxy-C<sub>2</sub>-C<sub>4</sub>-alkenyloxy, C<sub>2</sub>-C<sub>8</sub>-alkenyloxy-C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-alkylthio-C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>8</sub>-alkylsulphonyl-C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-alkylthio-

- 50 -

C<sub>1</sub>-C<sub>4</sub>-(hydroxy)alkoxy, unsubstituted or mono-, di- or tri-C<sub>1</sub>-C<sub>4</sub>-alkyl-, -C<sub>1</sub>-C<sub>4</sub>-alkoxy-, -hydroxy-, -C<sub>1</sub>-C<sub>4</sub>-alkylamino-, -di-C<sub>1</sub>-C<sub>4</sub>-alkylamino-, -halo- and/or -trifluoromethyl-substituted phenyl- or naphthyl-C<sub>1</sub>-C<sub>4</sub>-alkoxy, polyhalo-C<sub>1</sub>-C<sub>4</sub>-alkoxy, optionally partially hydrogenated pyridyl- or N-oxidopyridyl-C<sub>1</sub>-C<sub>4</sub>-alkoxy, thiazolyl-C<sub>1</sub>-C<sub>4</sub>-alkoxy, optionally N-oxidized morpholino-C<sub>1</sub>-C<sub>4</sub>-alkoxy, thiazolylthio-C<sub>1</sub>-C<sub>4</sub>-alkoxy, thiazolinythio-C<sub>1</sub>-C<sub>4</sub>-alkoxy, imidazolylthio-C<sub>1</sub>-C<sub>4</sub>-alkoxy, optionally N-oxidized pyridylthio-C<sub>1</sub>-C<sub>4</sub>-alkoxy, pyrimidinylthio-C<sub>1</sub>-C<sub>4</sub>-alkoxy, amino-C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-alkylamino-C<sub>1</sub>-C<sub>4</sub>-alkoxy, N,N-di-C<sub>1</sub>-C<sub>4</sub>-alkylamino-C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>8</sub>-alkanoylamino-C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>8</sub>-alkylsulphonylamino-C<sub>1</sub>-C<sub>4</sub>-alkoxy, trifluoro-C<sub>1</sub>-C<sub>8</sub>-alkylsulphonyl-C<sub>1</sub>-C<sub>4</sub>-alkoxy, pyrrolidino-C<sub>1</sub>-C<sub>4</sub>-alkoxy, piperidino-C<sub>1</sub>-C<sub>4</sub>-alkoxy, cyano-C<sub>1</sub>-C<sub>4</sub>-alkoxy, carboxy-C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-alkoxycarbonyl-C<sub>1</sub>-C<sub>4</sub>-alkoxy, carbamoyl-C<sub>1</sub>-C<sub>4</sub>-alkoxy, N-C<sub>1</sub>-C<sub>8</sub>-alkylcarbamoyl-C<sub>1</sub>-C<sub>4</sub>-alkoxy or N-mono- or N,N-di-C<sub>1</sub>-C<sub>4</sub>-alkylcarbamoyl-C<sub>1</sub>-C<sub>4</sub>-alkoxy, carboxy-C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-alkoxycarbonyl-C<sub>1</sub>-C<sub>4</sub>-alkyl, carbamoyl-C<sub>1</sub>-C<sub>8</sub>-alkyl, N-mono- or N,N-di-C<sub>1</sub>-C<sub>4</sub>-alkylcarbamoyl-C<sub>1</sub>-C<sub>4</sub>-alkyl, carboxy-C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-alkoxycarbonyl-C<sub>1</sub>-C<sub>4</sub>-alkoxy, carbamoyl-C<sub>1</sub>-C<sub>8</sub>-alkoxy, N-Mono- or N,N-di-C<sub>1</sub>-C<sub>4</sub>-alkylcarbamoyl-C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-alkylamino or N,N-di-C<sub>1</sub>-C<sub>4</sub>-alkylamino, or salt or prodrug thereof, or where one or more atoms are replaced by their stable, non-radioactive isotopes, preferably pharmaceutically usable salt thereof.

2. Compound according to Claim 1, where

R<sub>1</sub> is a) hydrogen; or

b) C<sub>1</sub>-C<sub>8</sub>-alkyl or C<sub>3</sub>-C<sub>8</sub>-cycloalkyl;

R<sub>2</sub> is a) C<sub>1</sub>-C<sub>8</sub>-alkyl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl, C<sub>1</sub>-C<sub>8</sub>-alkanoyl, heterocyclyl-C<sub>1</sub>-C<sub>8</sub>-alkanoyl, C<sub>3</sub>-C<sub>12</sub>-cycloalkyl-C<sub>1</sub>-C<sub>8</sub>-alkanoyl or aryl-C<sub>1</sub>-C<sub>8</sub>-alkanoyl, which radicals may be substituted by 1-4 C<sub>1</sub>-C<sub>8</sub>-alkyl, C<sub>1-6</sub>-alkylamino, cyano, halogen, hydroxyl, C<sub>1</sub>-C<sub>6</sub>-alkanoylamino, C<sub>1</sub>-C<sub>8</sub>-alkoxy, oxo, trifluoromethyl or aryl; or

b) together with R<sub>1</sub> and the nitrogen atom to which they are bonded are a saturated or partly unsaturated, 4-8-membered, heterocyclic ring which may contain an additional nitrogen or oxygen atom, in which case the additional nitrogen atom may optionally be substituted by C<sub>1</sub>-C<sub>8</sub>-alkyl or C<sub>1</sub>-C<sub>8</sub>-alkanoyl, and this heterocyclic ring may be part of a bicyclic or tricyclic ring system having a total of up to 16 ring members and the second ring may also contain a nitrogen or oxygen atom, in which case the nitrogen atom of the second ring may optionally be substituted by C<sub>1</sub>-C<sub>8</sub>-alkyl or C<sub>1</sub>-C<sub>8</sub>-alkanoyl, and all ring systems mentioned may be substituted by 1-4 C<sub>1</sub>-C<sub>8</sub>-alkyl, hydroxyl, oxo, C<sub>1</sub>-C<sub>8</sub>-alkoxy, C<sub>1</sub>-C<sub>8</sub>-alkoxy-C<sub>1</sub>-C<sub>8</sub>-alkoxy, C<sub>1</sub>-C<sub>8</sub>-alkanoylamino or aryloxy-C<sub>0</sub>-C<sub>4</sub>-alkyl-C<sub>1</sub>-C<sub>8</sub>-alkoxy;

R<sub>3</sub> is hydrogen;

- 51 -

R<sub>4</sub> is hydrogen;


R<sub>5</sub> are each independently hydrogen or C<sub>1</sub>-C<sub>8</sub>-alkyl;

R<sub>6</sub> is hydrogen;

R are each independently 1-4 radicals selected from:

hydrogen, C<sub>1</sub>-C<sub>8</sub>-alkyl, halogen, trifluoromethyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy-C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy-C<sub>1</sub>-C<sub>4</sub>-alkoxy-C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>8</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-alkoxy-C<sub>1</sub>-C<sub>4</sub>-alkoxy, or pharmaceutically usable salt thereof.

3. Compound according to Claim 1 of the formula



where R, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are each as defined in Claim 1.

4. Compound according to Claim 1,

where R<sub>2</sub> together with R<sub>1</sub> and the nitrogen atom to which they are bonded is a substituted or unsubstituted heterocyclic ring selected from pyrrolidino, piperidino, pyridinyl, piperazino, morpholino, thiomorpholino, furanyl, tetrahydrofuranyl, pyranyl, tetrahydropyranyl, thiazolyl, oxazolyl, imidazolyl, indolyl, isoindolyl, 2,3-dihydrobenzimidazolyl, 1,2,3,4-tetrahydroquinolyl, 1,2,3,4-tetrahydroisoquinolyl, 1,2,3,4-tetrahydro-1,3-benzodiazinyl, 1,2,3,4-tetrahydro-1,4-benzodiazinyl, 3,4-dihydro-2H-1,4-benzoxazinyl, 3,4-dihydro-2H-1,4-benzothiazinyl, 3,4-dihydro-2H-1,3-benzothiazinyl, 3,4,5,6,7,8-hexahydro-2H-1,4-benzoxazinyl, 3,4,5,6,7,8-hexahydro-2H-1,4-benzothiazinyl, 9-azabicyclo[3.3.1]non-9-yl, 1-azepan-1-yl, 2,8-diazaspiro[4.5]dec-8-yl, octahydroisoindol-2-yl, 4-azatricyclo[5.2.1.0<sup>2,6</sup>]dec-4-yl, 3-azabicyclo[3.2.1]oct-3-yl, 3,7-diazabicyclo[3.3.1]non-3-yl, 3-azabicyclo[3.3.1]non-3-yl, 8-azabicyclo[3.2.1]oct-8-yl, 3-azabicyclo[3.2.2]non-3-yl, 2,3,4,5-tetrahydro-1H-1-benz[6,7-b]azepinyl and 5,6-dihydrophenanthridinyl.

5. Compound according to one of Claims 1-4 for use in a method for therapeutically treating the human or animal body.

- 52 -

6. Pharmaceutical preparation comprising, as an active pharmaceutical ingredient, a compound according to one of Claims 1-4 in free form or as a pharmaceutically usable salt.

7. Use of a compound according to one of Claims 1 - 4 for the preparation of a pharmaceutical preparation with renin-inhibiting action.

8. Use of a compound according to one of Claims 1 - 4 for the preparation of a pharmaceutical preparation for the treatment or prevention of hypertension, heart failure, glaucoma, cardiac infarction, kidney failure or restenosis.